ISIS Pharmaceuticals, Inc. : Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a)

16-11-2013 4-tradersComments (0)

Isis PharmaceuticalsPharmaceutical

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-APO(a)Rx.  These data were presented by Dr. Sotirios Tsimikas at the Vascular Biology Working Group global chapter meeting occurring concurrently with the American...

Read more on 4-traders

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top